Video yรผkleniyor...

Video Yรผklenemedi

Ana Sayfaya Dรถn

๐‰๐ž๐Ÿ๐Ÿ๐ž๐ซ๐ข๐ž๐ฌ ๐‹๐จ๐ง๐๐จ๐ง: Olema Oncology more than doubled yesterday when Roche announced surprise data for its oral SERD - the CEO reacts and shares the development program for Olema's competing asset. $OLEM Full video:

BiotechTV's profile picture

BiotechTV

10,176 subscribers

12,936 gรถrรผntรผleme โ€ข 10 ay รถnce โ€ขvia X (Twitter)

LIVE

Anya Rossiโ€ข Live Now

Private livecam show

0 Yorum

Yorum bulunmuyor

Orijinal gรถnderinin yorumlarฤฑ burada gรถrรผnecek

Benzer Videolar

๐‰๐ž๐Ÿ๐Ÿ๐ž๐ซ๐ข๐ž๐ฌ ๐‹๐จ๐ง๐๐จ๐ง: Affinity Asset Advisors' Patrick Nosker shares a public investor's perspective on biotech and comments on a few of his firm's top positions. $XBI $XENE $MDGL $ALKS Full video:
4:30

๐‰๐ž๐Ÿ๐Ÿ๐ž๐ซ๐ข๐ž๐ฌ ๐‹๐จ๐ง๐๐จ๐ง: Affinity Asset Advisors' Patrick Nosker shares a public investor's perspective on biotech and comments on a few of his firm's top positions. $XBI $XENE $MDGL $ALKS Full video:

BiotechTV

13,777 gรถrรผntรผleme โ€ข 10 ay รถnce

๐…๐ซ๐จ๐ฆ ๐๐˜๐’๐„: AstraZeneca's CEO Pascal Soriot shares his take on M&A, oncology, Baxfendy for hypertension, the obesity market, and more. $AZN Full video:
4:58

๐…๐ซ๐จ๐ฆ ๐๐˜๐’๐„: AstraZeneca's CEO Pascal Soriot shares his take on M&A, oncology, Baxfendy for hypertension, the obesity market, and more. $AZN Full video:

BiotechTV

36,428 gรถrรผntรผleme โ€ข 3 ay รถnce

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: After switching to a new GalNAc-LNP delivery vehicle a year ago, @VerveTx today announced the initial safety and efficacy data from its VERVE-102 PCSK9 based editor. Co-Founder & CEO Sek Kathiresan MD covers the data. $VERV Full video:
5:19

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: After switching to a new GalNAc-LNP delivery vehicle a year ago, @VerveTx today announced the initial safety and efficacy data from its VERVE-102 PCSK9 based editor. Co-Founder & CEO Sek Kathiresan MD covers the data. $VERV Full video:

BiotechTV

22,484 gรถrรผntรผleme โ€ข 1 yฤฑl รถnce

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: Abivax CEO Marc de Garidel discusses freshly released maintenance part 2 results for obefazimod in UC and describes how he believes it builds on initial data announced earlier this month. $ABVX Watch the full video:
3:01

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: Abivax CEO Marc de Garidel discusses freshly released maintenance part 2 results for obefazimod in UC and describes how he believes it builds on initial data announced earlier this month. $ABVX Watch the full video:

BiotechTV

22,305 gรถrรผntรผleme โ€ข 2 ay รถnce

๐๐ซ๐ข๐ ๐ก๐ญ ๐Œ๐ข๐ง๐๐ฌ: William Blair Senior Biotech Analyst Andy Hsieh reacts to today's oral obesity data from Viking's VK2735 and recent data from Lilly's orforglipron. $VKTX $LLY Full video:
13:02

๐๐ซ๐ข๐ ๐ก๐ญ ๐Œ๐ข๐ง๐๐ฌ: William Blair Senior Biotech Analyst Andy Hsieh reacts to today's oral obesity data from Viking's VK2735 and recent data from Lilly's orforglipron. $VKTX $LLY Full video:

BiotechTV

68,717 gรถrรผntรผleme โ€ข 1 yฤฑl รถnce

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: Corvus Pharma CEO Richard Miller fields follow-up questions about last week's atopic dermatitis data for the ITK inhibitor soquelitinib. $CRVS Full video:
4:58

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: Corvus Pharma CEO Richard Miller fields follow-up questions about last week's atopic dermatitis data for the ITK inhibitor soquelitinib. $CRVS Full video:

BiotechTV

24,695 gรถrรผntรผleme โ€ข 7 ay รถnce

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: Solid Biosciences's CEO Bo Cumbo discusses today's data release of the company's microdystrophin gene therapy candidate for Duchenne muscular dystrophy. $SLDB Full video:
7:29

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: Solid Biosciences's CEO Bo Cumbo discusses today's data release of the company's microdystrophin gene therapy candidate for Duchenne muscular dystrophy. $SLDB Full video:

BiotechTV

42,193 gรถrรผntรผleme โ€ข 1 yฤฑl รถnce

๐’๐… ๐‡๐ž๐š๐ฅ๐ญ๐ก๐œ๐š๐ซ๐ž ๐–๐ž๐ž๐ค: Sana Bio's CEO Steve Harr describes the science behind the company's cell therapy program that aims to be a cure for type 1 diabetes. $SANA Full video:
4:40

๐’๐… ๐‡๐ž๐š๐ฅ๐ญ๐ก๐œ๐š๐ซ๐ž ๐–๐ž๐ž๐ค: Sana Bio's CEO Steve Harr describes the science behind the company's cell therapy program that aims to be a cure for type 1 diabetes. $SANA Full video:

BiotechTV

19,210 gรถrรผntรผleme โ€ข 8 ay รถnce

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: With three approved products and filings for more over the near term, Axsome Therapeutics's CEO describes the scale and reach this company is building in the CNS space. $AXSM Full video:
3:36

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: With three approved products and filings for more over the near term, Axsome Therapeutics's CEO describes the scale and reach this company is building in the CNS space. $AXSM Full video:

BiotechTV

20,950 gรถrรผntรผleme โ€ข 1 yฤฑl รถnce

๐’๐… ๐‡๐ž๐š๐ฅ๐ญ๐ก๐œ๐š๐ซ๐ž ๐–๐ž๐ž๐ค: Abivax CEO Marc de Garidel reflects on a breakout 2025 for obefazimod and key data that will read out this year. $ABVX Full video:
3:51

๐’๐… ๐‡๐ž๐š๐ฅ๐ญ๐ก๐œ๐š๐ซ๐ž ๐–๐ž๐ž๐ค: Abivax CEO Marc de Garidel reflects on a breakout 2025 for obefazimod and key data that will read out this year. $ABVX Full video:

BiotechTV

73,893 gรถrรผntรผleme โ€ข 8 ay รถnce

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: Roche will pay Manifold Bio $55M up front, and up to $2B in milestones, to collaborate on multiple next-generation brain shuttles for neurological diseases. Full video:
4:17

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: Roche will pay Manifold Bio $55M up front, and up to $2B in milestones, to collaborate on multiple next-generation brain shuttles for neurological diseases. Full video:

BiotechTV

18,780 gรถrรผntรผleme โ€ข 10 ay รถnce

๐ŸšจWATCH: The push for green energy is running head first into the push for data centers. Spotsylvania County, Virginia is home to the largest solar panel development east of the Rockies. But despite its large 6,300+ acre footprint, it doesnโ€™t provide enough power for one large data center complex in Loudoun County. Loudoun County has more than 200 data centers, and Virginia has more than 600 data centers. More data centers are on the way.
2:47

๐ŸšจWATCH: The push for green energy is running head first into the push for data centers. Spotsylvania County, Virginia is home to the largest solar panel development east of the Rockies. But despite its large 6,300+ acre footprint, it doesnโ€™t provide enough power for one large data center complex in Loudoun County. Loudoun County has more than 200 data centers, and Virginia has more than 600 data centers. More data centers are on the way.

Nick Minock

164,710 gรถrรผntรผleme โ€ข 2 ay รถnce

๐Ž๐Ÿ๐Ÿ-๐“๐š๐ซ๐ ๐ž๐ญ ๐„๐Ÿ๐Ÿ๐ž๐œ๐ญ๐ฌ: BridgeBio Pharma Founder & CEO Neil Kumar and Roivant Sciences CEO Matt Gline discusses the hub and spoke biotech model and trying to build a sustainable business for the long-term. $BBIO $ROIV Watch the full episode:
6:11

๐Ž๐Ÿ๐Ÿ-๐“๐š๐ซ๐ ๐ž๐ญ ๐„๐Ÿ๐Ÿ๐ž๐œ๐ญ๐ฌ: BridgeBio Pharma Founder & CEO Neil Kumar and Roivant Sciences CEO Matt Gline discusses the hub and spoke biotech model and trying to build a sustainable business for the long-term. $BBIO $ROIV Watch the full episode:

BiotechTV

11,722 gรถrรผntรผleme โ€ข 4 ay รถnce

The Government has announced the details of its infrastructure plans for the next five years. The revised National Development Plan includes โ‚ฌ112bn funding for housing, energy, water and transport projects | Read more:
0:36

The Government has announced the details of its infrastructure plans for the next five years. The revised National Development Plan includes โ‚ฌ112bn funding for housing, energy, water and transport projects | Read more:

RTร‰ News

17,012 gรถrรผntรผleme โ€ข 1 yฤฑl รถnce

๐…๐ซ๐จ๐ฆ ๐๐˜๐’๐„: ArsenalBio Co-Founder & CEO ken drazan talks about engineering the next generation of T-cell therapies, including a clinical stage renal cell program that includes multiple features. Full video:
3:45

๐…๐ซ๐จ๐ฆ ๐๐˜๐’๐„: ArsenalBio Co-Founder & CEO ken drazan talks about engineering the next generation of T-cell therapies, including a clinical stage renal cell program that includes multiple features. Full video:

BiotechTV

11,057 gรถrรผntรผleme โ€ข 1 yฤฑl รถnce